Your browser doesn't support javascript.
loading
Towards global consensus on core outcomes for hidradenitis suppurativa research: an update from the HISTORIC consensus meetings I and II.
Thorlacius, L; Garg, A; Ingram, J R; Villumsen, B; Theut Riis, P; Gottlieb, A B; Merola, J F; Dellavalle, R; Ardon, C; Baba, R; Bechara, F G; Cohen, A D; Daham, N; Davis, M; Emtestam, L; Fernández-Peñas, P; Filippelli, M; Gibbons, A; Grant, T; Guilbault, S; Gulliver, S; Harris, C; Harvent, C; Houston, K; Kirby, J S; Matusiak, L; Mehdizadeh, A; Mojica, T; Okun, M; Orgill, D; Pallack, L; Parks-Miller, A; Prens, E P; Randell, S; Rogers, C; Rosen, C F; Choon, S E; van der Zee, H H; Christensen, R; Jemec, G B E.
Afiliação
  • Thorlacius L; Department of Dermatology, Zealand University Hospital, Roskilde, Health Sciences Faculty, University of Copenhagen, Denmark.
  • Garg A; Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, the Capital Region of Denmark, Copenhagen, Denmark.
  • Ingram JR; Department of Dermatology, Hofstra Northwell School of Medicine, New Hyde Park, NY, U.S.A.
  • Villumsen B; Institute of Infection and Immunity, University Hospital of Wales, Heath Park, Cardiff, U.K.
  • Theut Riis P; Patient Representative, The Patients' Association HS Denmark, Denmark.
  • Gottlieb AB; Department of Dermatology, Zealand University Hospital, Roskilde, Health Sciences Faculty, University of Copenhagen, Denmark.
  • Merola JF; Department of Dermatology, New York Medical College, Valhalla, NY, U.S.A.
  • Dellavalle R; Harvard Medical School, Boston, MA, U.S.A.
  • Ardon C; Department of Dermatology and Department of Medicine, Division of Rheumatology.
  • Baba R; Dermatology Service, U.S. Department of Veteran Affairs Medical Centre, Denver, CO, U.S.A.
  • Bechara FG; Department of Dermatology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.
  • Cohen AD; Former National Advisor to the Ministry of Health, Malaysia.
  • Daham N; Department of Dermatologic Surgery, St Josef Hospital, Ruhr-University, Bochum, Germany.
  • Davis M; Siaal Research Center for Family Medicine and Primary Care, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Emtestam L; Chief Physician's Office, Department of Quality Measurements and Research, Clalit Health Services, Tel-Aviv, Israel.
  • Fernández-Peñas P; Department of Dermatology, Tufts Medical Center, Boston, MA, U.S.A.
  • Filippelli M; Department of Dermatology, Mayo Clinic, Rochester, MN, 5590, U.S.A.
  • Gibbons A; Department of Dermatology, Karolinska University Hospital, Stockholm, Sweden.
  • Grant T; Department of Dermatology, Westmead Hospital, Sydney Medical School, The University of Sydney, Sydney, Australia.
  • Guilbault S; Patient Representative, Morgantown, WV, U.S.A.
  • Gulliver S; Patient Representatives, The Hidradenitis Suppurativa Trust, Rochester, U.K.
  • Harris C; Patient Representative, Tucson, AZ, U.S.A.
  • Harvent C; Patient Representative, Hope for HS, Detroit, MI, U.S.A.
  • Houston K; Department of Research, Newlab Clinical Research, NL, Canada.
  • Kirby JS; Patient Representative, Cardiff, U.K.
  • Matusiak L; Patient Representative, Patients' Association: La Maladie de Verneuil en Belgique, Erbisoeul, Belgium.
  • Mehdizadeh A; Patient Representatives, The Hidradenitis Suppurativa Trust, Rochester, U.K.
  • Mojica T; Department of Dermatology, Penn State Hershey Medical Center, Hershey, PA, U.S.A.
  • Okun M; Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland.
  • Orgill D; Dalla Lana School of Public Health, University of Toronto, ON, Canada.
  • Pallack L; Patient Representative, Brick, NJ, U.S.A.
  • Parks-Miller A; Fort HealthCare, Fort Atkinson, WI, U.S.A.
  • Prens EP; Division of Plastic Surgery, Brigham and Women's Hospital, Boston, MA, U.S.A.
  • Randell S; Patient Representative, Longmont, CO, U.S.A.
  • Rogers C; Hope for HS, Detroit, MI, U.S.A.
  • Rosen CF; Hidradenitis Suppurativa Foundation, Inc., Santa Monica, CA, U.S.A.
  • Choon SE; Department of Dermatology, Henry Ford Hospital, Detroit, MI, U.S.A.
  • van der Zee HH; Dermatology Service, U.S. Department of Veteran Affairs Medical Centre, Denver, CO, U.S.A.
  • Christensen R; Patient Representative, Hope for HS, Detroit, MI, U.S.A.
  • Jemec GBE; Patient Representative, HS Aware, Toronto, ON, Canada.
Br J Dermatol ; 178(3): 715-721, 2018 03.
Article em En | MEDLINE | ID: mdl-29080368
ABSTRACT

BACKGROUND:

A core outcomes set (COS) is an agreed minimum set of outcomes that should be measured and reported in all clinical trials for a specific condition. Hidradenitis suppurativa (HS) has no agreed-upon COS. A central aspect in the COS development process is to identify a set of candidate outcome domains from a long list of items. Our long list had been developed from patient interviews, a systematic review of the literature and a healthcare professional survey, and initial votes had been cast in two e-Delphi surveys. In this manuscript, we describe two in-person consensus meetings of Delphi participants designed to ensure an inclusive approach to generation of domains from related items.

OBJECTIVES:

To consider which items from a long list of candidate items to exclude and which to cluster into outcome domains.

METHODS:

The study used an international and multistakeholder approach, involving patients, dermatologists, surgeons, the pharmaceutical industry and medical regulators. The study format was a combination of formal presentations, small group work based on nominal group theory and a subsequent online confirmation survey.

RESULTS:

Forty-one individuals from 13 countries and four continents participated. Nine items were excluded and there was consensus to propose seven domains disease course, physical signs, HS-specific quality of life, satisfaction, symptoms, pain and global assessments.

CONCLUSIONS:

The HISTORIC consensus meetings I and II will be followed by further e-Delphi rounds to finalize the core domain set, building on the work of the in-person consensus meetings.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hidradenite Supurativa Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hidradenite Supurativa Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article